<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02241694</url>
  </required_header>
  <id_info>
    <org_study_id>F7HAEM-4146</org_study_id>
    <secondary_id>U1111-1147-4202</secondary_id>
    <nct_id>NCT02241694</nct_id>
  </id_info>
  <brief_title>To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives</brief_title>
  <acronym>HERO</acronym>
  <official_title>Haemophilia, Experiences, Results and Opportunities (HERO) in Brazil: Assessment of Psychological Effects of Haemophilia on Patients and Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is conducted in South America. The purpose is to identify the key psychosocial
      issues affecting patients with haemophilia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative assessments of perceived impact on daily life</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived disease control</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carrier status and reactions to haemophilia diagnosis</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic counselling and testing</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of haemophilia in siblings</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with support from partners, family, friends, others</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual intimacy with partners in long-term relationships</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment method, compliance and location</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified WHO-5 (World Health Organization-Five Well Being Index)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge and information about haemophilia</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in haemophilia care</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia B</condition>
  <condition>Haemophilia A With Inhibitors</condition>
  <condition>Haemophilia B With Inhibitors</condition>
  <condition>Relatives to/Carers of Patients</condition>
  <arm_group>
    <arm_group_label>survey</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>No treatment given. Participants are to complete a questionnaire in the study.</description>
    <arm_group_label>survey</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males with haemophilia and parents/carers of children with haemophilia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 18 years or above with haemophilia A or B (with or without inhibitors) OR
             Parents/caregivers of children/adolescents younger than 18 years with haemophilia A or
             B (with or without inhibitors); only one subject per household will be able to
             participate

          -  Patients currently receiving one of the following treatments: a. replacement factor
             VIII therapy, b. replacement factor IX therapy, c. bypassing agents (recombinant
             factor VIIa or APCC) OR Patients with haemophilia, not receiving any kind of treatment
             with replacement factor VIII or IX or a bypassing agent (as appropriate), but who have
             had at least one spontaneous haemorrhage into one or more joints within the last 12
             months

          -  The participants (patients with haemophilia and parents/caregivers for patients under
             18 years old) must be able to complete a paper questionnaire in order to participate
             in the study

          -  Providing informed consent before the start of any study-related activities

        Exclusion Criteria:

          -  Inability for the patients or parents/caregivers to understand and comply with verbal
             instructions, unless assisted by a member of the HTC (Haemophilia Treatment Center) or
             by a relative. (No other conditions were established for patients who cannot read or
             write to be able to participate in this study in addition to the need of help from a
             member of HTC or by a relative.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452), GZZF</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>SÃ¤o Paulo</city>
        <zip>05001-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2014</study_first_submitted>
  <study_first_submitted_qc>September 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

